Eli Lilly and Company $LLY is Cozad Asset Management Inc.’s 10th Largest Position

Cozad Asset Management Inc. increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.1% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 22,031 shares of the company’s stock after purchasing an additional 452 shares during the quarter. Eli Lilly and Company accounts for 1.6% of Cozad Asset Management Inc.’s holdings, making the stock its 10th biggest holding. Cozad Asset Management Inc.’s holdings in Eli Lilly and Company were worth $20,263,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of LLY. Allen Capital Group LLC grew its holdings in Eli Lilly and Company by 0.8% during the 1st quarter. Allen Capital Group LLC now owns 1,918 shares of the company’s stock worth $1,764,000 after acquiring an additional 16 shares in the last quarter. Security Financial Services INC. raised its holdings in shares of Eli Lilly and Company by 2.0% in the 1st quarter. Security Financial Services INC. now owns 1,281 shares of the company’s stock valued at $1,178,000 after purchasing an additional 25 shares in the last quarter. Axiom Investment Management LLC purchased a new stake in shares of Eli Lilly and Company in the 1st quarter worth approximately $1,297,000. Summitry LLC boosted its stake in shares of Eli Lilly and Company by 76.0% during the first quarter. Summitry LLC now owns 1,477 shares of the company’s stock valued at $1,358,000 after purchasing an additional 638 shares in the last quarter. Finally, WNY Asset Management LLC purchased a new position in Eli Lilly and Company during the first quarter valued at approximately $5,121,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $1,149.28 on Friday. The business’s fifty day simple moving average is $1,152.66 and its 200-day simple moving average is $1,044.16. The company has a market cap of $1.08 trillion, a PE ratio of 40.83, a PEG ratio of 1.43 and a beta of 0.51. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same quarter last year, the firm earned $3.34 EPS. The business’s quarterly revenue was up 55.5% on a year-over-year basis. Analysts expect that Eli Lilly and Company will post 34.91 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Bank of America upped their target price on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a report on Friday, July 10th. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a report on Monday, June 15th. JPMorgan Chase & Co. upped their price objective on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 7th. Leerink Partners raised their price objective on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. Finally, UBS Group lifted their target price on Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $1,283.64.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly continues to pull ahead of Novo Nordisk in the rapidly expanding obesity-treatment market, with significantly stronger recent revenue growth and a more favorable outlook. Lilly’s latest reported quarter included 55.5% year-over-year revenue growth, while Novo Nordisk expects an adjusted sales decline. Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed.
• Positive Sentiment: The company is investing another $750 million with Resilience to expand U.S. manufacturing capacity for diabetes and obesity medicines. The project is expected to add at least 400 jobs and supports Lilly’s ability to meet continued demand. Lilly Boosts Diabetes and Obesity Capacity With $750 Million Deal
• Positive Sentiment: Completion of a late-stage retatrutide trial provides a potential future catalyst in diabetes, obesity and related cardiovascular indications. Lilly has also begun an early-stage study of eloralintide, adding another candidate to its weight-loss pipeline. Lilly’s Retatrutide Trial Completion Signals Next Wave in Diabetes and Obesity Drugs
• Neutral Sentiment: Analysts are focused on key operating metrics for Lilly’s second-quarter results, including demand, prescription trends and guidance. The company’s prior earnings report substantially exceeded estimates, raising expectations for the upcoming release. Lilly Q2 Earnings on the Horizon
• Negative Sentiment: Weight-loss drug stocks came under pressure as investors digested clinical-trial news and positioned ahead of earnings. Technical selling intensified after Lilly fell below a closely watched support level, despite its stronger long-term fundamentals. Weight Loss Drug Stocks Slump

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.